This Biotech Company (PKTX) And Their "Revolutionary Discovery" Are Must Know Material Ahead Of Wednesday
We have a lot to go over so let's dive in.
I recently had an interesting idea come across my desk and felt it necessary to bring it to your attention ASAP. Here's why...
Multiple market opportunities.
When 2025 rolls around, you could be looking at the following potential industry sizes:
- Ophthalmology industry is $35.7Bn (1)
- Dermatology industry is $183Bn (2)
- Organ transplant industry is $51Bn (3)
- Biomanufacturing industry is $218Bn (4)
Choke on those for a second. LOL.
Now, this company who has recently moved above several lines of potential support in recent days could be nearing a game-changing discover that could shape future medical industries forever.
For Wednesday, March 23rd, there is one Biotech profile to have at the top of your watch-list:
*ProtoKinetix, Incorporated (PKTX)*
ProtoKinetix is a research and development company leading the way in cell survival solutions. AAGP, their patented anti-aging glycopeptide, is a revolutionary discovery that could shape the future of ophthalmology, dermatology, transplant support and biomanufacturing.
And right now, this profile has 5 potential catalysts to know ahead of Wednesday's opening bell. Check them out:
No. 1 - Potential Support Levels Could Be Strengthening
No. 2 - Company Selects Two AAGP Formulations To Advance Into Preclinical Efficacy Testing
No. 3 - Partnering With NYSE Company To Accelerate Development Of AAGP
No. 4 - Resumption Of Phase 1b Clinical Trials For Use Of AAGP Treated Islet Cells
No. 5 - Peer Reviewed Research Publication Interpreting Results Examining Benefit Provided By AAGP
But more on those in a second...
ProtoKinetix Patented Molecule - Anti-Aging Glycopeptide (AAGP)
AAGP key benefits
AAGPs are small, stable molecules that display abilities in resolving challenges confronting medical researchers in regenerative medicine. Because of its molecular makeup, AAGP should function without side effects common in other treatments.
By regenerating retinal cells in humans and animals, AAGP has the potential to treat millions suffering from dry eyes and blindness.
According to the Centers for Disease Control and Prevention, as many as 12 million Americans live with vision impairment. By regenerating retinal cells in humans, AAGP has the potential to treat people suffering from eye conditions.
The company is researching three major ways that AAGP can help: retinal cell transplantation, ocular inflammation and veterinary treatments.
Compared to preventative skincare products that need to be applied before environmental exposure, AAGP can recover skin cells after the damage is done, as demonstrated in a laboratory setting.
Chronic skin conditions can be both physically and mentally painful. In the United States, more than 85 million people are affected by skin conditions each year, according to the American Academy of Dermatology. AAGP can recover skin cells after the damage is done, as demonstrated in a laboratory setting. As a result, this molecule has the potential to make treatments for skin conditions more accessible and affordable.
The company is researching two major ways that AAGP can help: inflammation protection as well as UV-radiation and burn recovery.
During today’s transplants, organs can only survive around four hours. With AAGP, they hope to extend their viability to 24 hours.
The impact: About 80 people receive transplants each day according to the Health Resources & Services Administration.
In the realm of cell therapy and cancer immunotherapy, AAGP could be the link to essential advancements.
The impact: Over 1 million people have been treated by cell therapies worldwide according to the Transparency Market Research.
Find sources and more details at the company website.
And right now, PKTX has 5 potential catalysts to firmly know. Check them out:
No. 1 PKTX Potential Catalyst - Potential Support Levels Could Be Strengthening
Strong support levels could be growing for PKTX.
Take a look: